liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
HIF-2 alpha Expression Is Suppressed in SCLC Cells, Which Survive in Moderate and Severe Hypoxia When HIF-1 alpha Is Repressed
Lund University.
Lund University.
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Health Sciences.
Lund University.
Show others and affiliations
2012 (English)In: American Journal of Pathology, ISSN 0002-9440, E-ISSN 1525-2191, Vol. 180, no 2, 494-504 p.Article in journal (Refereed) Published
Abstract [en]

Small cell lung carcinoma (SCLC) is extremely aggressive and frequently metastasizes widely in its early stage. Because tumor hypoxia is related to aggressive tumor behavior and the hypoxic adaptation of SCLC is poorly documented, we stained SCLC tumors arranged in a tissue microarray for hypoxia-inducible factor (HIF)-1 alpha and HIF-2 alpha proteins. We found an overall lack of HIF-2 alpha protein expression, which was confirmed in large tumor sections. HIF-1 alpha protein was strongly expressed in most tumors, frequently adjacent to necrotic regions. In concordance, cultured SCLC but not non-small cell lung carcinoma cells showed no or extremely low levels of HIF-2 alpha mRNA and no HIF-2 alpha protein at hypoxia. HIF-1 alpha was stabilized after 4 hours at hypoxia, and its accumulation increased up to 96 hours. SCLC cells survived well and showed net proliferation and low cell death in modest (1% oxygen) and severe (0.1% oxygen) hypoxia. HIF-1 alpha repression virtually did not influence cell death or viability despite reduced levels of hypoxia-inducible genes, such as BNIP3 and BNIP3L. At 1% oxygen no increased autophagy (LC3B-II activation) or NF-kappa B signaling were detected, whereas the unfolded protein response was activated at severe hypoxia. Our data indicate that HIFs are not exclusively required for SCLC cell survival at modest or severe hypoxia and that additional, yet uncharacterized, hypoxia-driven adaptation pathways may become activated.

Place, publisher, year, edition, pages
Elsevier , 2012. Vol. 180, no 2, 494-504 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-75470DOI: 10.1016/j.ajpath.2011.10.014ISI: 000299918800007OAI: diva2:507082
Funding Agencies|Swedish Cancer Society||Childrens Cancer Foundation of Sweden||Swedish Foundation of Strategic Research||SSF Strategic Center for Translational Cancer Research-CREATE Health||Strategic Cancer Research Program||BioCARE||Hans von Kantzows Foundation||Gunnar Nilssons Cancer Foundation||Skane University Hospital||Available from: 2012-03-02 Created: 2012-03-02 Last updated: 2012-03-02

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Monsef, Nastaran
By organisation
Department of Clinical and Experimental MedicineFaculty of Health Sciences
In the same journal
American Journal of Pathology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 81 hits
ReferencesLink to record
Permanent link

Direct link